Molecular Prognostic and Predictive Biomarkers Based Targeted Treatment of Colorectal Cancer

This webcast is co-provided by A. Webb Roberts Center for CME of Baylor Health Care System and CancerNet.

For more information visit: www.cancernetus.com

Lilly USA, LLC
Genentech, Inc.

Scroll to the Bottom of this Information to Begin this Course

Release date: June 30, 2016

Valid through: June 30, 2017

Specialty: Oncology

Topic: Colorectal Cancer

Media: Internet

Estimated Time to Complete Activity: 2.0 hours (125 min)

CME Provider contact information: To contact CME provider, call 214 820 2317

CME Provider Privacy Policy and Contact Information

A. Webb Roberts Center for CME of Baylor Health Care System observes privacy and confidentiality of CME information and personal information of CME participants. Third parties receive only aggregated data about CME activities that are relevant to their interests and/or the activities they support. To contact CME Provider, call 214-820-2317.

Target Audience

This webcast is designed to meet the educational needs of medical oncologists and other health care professionals who diagnose, treat, and manage patients with colorectal cancer.

Statement of Need/Program Overview

This webcast is intended to improve care of patients with colorectal cancer by accelerating adoption of new guidelines and evidence-based practice change. In-depth discussion of novel agents at various stages of clinical development will be given significant focus. This Internet CME activity is designed to provide clinical decision-making strategies for integration of novel therapeutic options.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Describe the role of EGFR inhibitors in combination with chemotherapy in colorectal cancer (CRC) patients with KRAS and other mutations
  • Describe the current status of chemotherapy for colorectal cancer (CRC) and KRAS, BRAF, NRAS, PIK3CA and DNA mismatch repair mutations
  • Appraise the importance of predictive and prognostic biomarkers in CRC beyond KRAS
  • Identify BRAF mutant tumor types in CRC and promising treatment strategies

Credit Available

  • Physicians — maximum of 2.0 AMA PRA Category 1 Credits™

All other healthcare professionals completing this course will be issued a statement of participation.

Faculty

Axel Grothey, MD
Professor of Oncology,
Mayo Clinic,
Rochester, MN

Scott Kopetz, MD, PhD
Associate Professor,
Department of Gastrointestinal Medical Oncology,
The University of Texas MD Anderson Cancer Center,
Houston, TX

Wells Messersmith, MD
Associate Professor of Medicine,
Deputy Head,
Division of Medical Oncology,
Director,
Gastrointestinal Medical Oncology Program,
Program co-Leader,
Developmental Therapeutics,
University of Colorado
Denver, Aurora, CO

Christopher Lieu, MD
Assistant Professor,
Division of Medical Oncology,
University of Colorado Anschutz Medical Campus,
Aurora, CO

Physician Continuing Medical Education

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the co-providership of A. Webb Roberts Center for CME of Baylor Health Care System and CancerNet. The A. Webb Roberts Center for CME of Baylor Health Care System is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

The A. Webb Roberts Center for Continuing Medical Education of Baylor Health Care System designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures of Conflicts of Interest

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME webcast:

Axel Grothey, MD
  • No relevant financial relationships
Scott Kopetz, MD, PhD
  • Advisory Board: Genentech
Wells Messersmith, MD
  • Research Funding: Roche/Genentech, Pfizer
Christopher Lieu, MD
  • Consultant: Merrimack Pharmaceuticals

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME webcast:

Axel Grothey, MD
  • No relevant financial relationships
Kamatham A. Naidu, PhD (CancerNet)
  • No relevant financial relationships

All other individuals in a position to control content have no relevant financial relationships to disclose.

Instructions for Participation and Credit

There are no fees for participating and receiving CME credit for this webcast. During the period June 30, 2016 through June 30, 2017, participants must read all of the material and study the educational webcast.

This webcast includes text, graphics, and may include multimedia features. There are no fees for participating in or receiving credit for this webcast.

Click on all of the "medical education webcast" links and review the content presented. You must view all of the content to proceed to the post-test.

Read, complete, and submit answers to the post-test questions and evaluation questions online. You must answer all missed questions until you get them correct.

Participants must receive a test score of 100% in order to proceed to the course evaluation, and they must respond to all evaluation questions to receive a letter of credit.

If needed, you may save your answers and return to complete your course at a later date. You can find your saved course by selecting "Your Course History" on the left navigation bar. Then select "View" next to the course you would like to complete.

After submitting the webcast evaluation, you may access your letter of credit by selecting "Your Certificates" on the left navigation bar.

Select "Credit" to view letters of credit onscreen and print from your browser. You may print the letter of credit, but you may not alter the letter of credit.

Your credits will be tallied and may be viewed by selecting "View your transcripts" in the "Your Account" area.

Hardware and Software Requirements

Recommends version 6.x browsers or higher from Microsoft or Netscape. Certain educational activities may require additional software to view multimedia, presentation, or printable versions of content. These activities will be marked as such and will provide links to the required software. Required software may include:
Macromedia Flash
Apple QuickTime
Adobe Acrobat
Microsoft PowerPoint
Windows Media Player
RealNetworks RealOne Player
VLC Media Player